公开(公告)号：US20240101631A1

公开(公告)日：2024-03-28

申请号：US18484870

申请日：2023-10-11

Applicant: Merck Sharp & Dohme LLC

Inventor： Cristina Abrahams ,  Edward Bowman ,  Xiaofan Li ,  Songnian Lin ,  Willy Solis ,  Ryan Stafford ,  Aarron Willingham ,  Alice Yam ,  Junhao Yang ,  Gang Yin

IPC: C07K14/55 ,  A61K38/20 ,  A61K47/54 ,  A61K47/60 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61K47/545 ,  A61K47/60 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K38/00

Abstract: Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor βγc dimer over binding the IL-2 receptor αβγc trimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.

公开(公告)号：US20240100156A1

公开(公告)日：2024-03-28

申请号：US18166938

申请日：2023-02-09

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K38/16 ,  A61K39/00 ,  A61K39/085 ,  A61K47/68 ,  C07K14/31 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K38/164 ,  A61K39/0011 ,  A61K39/085 ,  A61K39/39541 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6851 ,  C07K14/31 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3053 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/40 ,  C07K2319/55 ,  C07K2319/74

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

公开(公告)号：US20240100107A1

公开(公告)日：2024-03-28

申请号：US18271619

申请日：2022-01-11

Applicant: Seneca Therapeutics, Inc.

Inventor： Paul L. HALLENBECK ,  Sunil CHADA

IPC: A61K35/768 ,  A61K9/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K35/768 ,  A61K9/0019 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507

Abstract: Provided herein are compositions and methods of using Seneca Valley Vims (SVV) or SVV derivative in combination with a checkpoint inhibitor for treating a cancer that is refractive to treatment by the checkpoint inhibitor. Also provided herein are kits containing a Seneca Valley Vims (SVV) or SVV derivative and a checkpoint inhibitor for treating a cancer that is refractive to treatment by the checkpoint inhibitor.

公开(公告)号：US11939385B2

公开(公告)日：2024-03-26

申请号：US16613774

申请日：2018-05-15

Applicant: ALX Oncology Inc.

Inventor： Marija Vrljic ,  Jaume Pons

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/54 ,  C07K16/32

CPC classification number: C07K16/2863 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/5428 ,  C07K14/5434 ,  C07K16/2818 ,  C07K16/32 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/62 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C07K2319/50

Abstract: The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N-terminus of the VH is fused to a first polypeptide shield moiety (S1), and the N-terminus of the VL is fused to a second polypeptide shield moiety (S2), wherein S1 comprises a first disease-sensing releasable moiety (DS1) and/or S2 comprises a second disease-sensing releasable moiety (DS2), wherein association of S1 with S2 blocks binding of the ABD to its target, and wherein the ABD does not specifically bind to S1, S2, or association thereof. Composition, methods of treatment using the activatable antibodies, and methods of preparation thereof are further provided.

公开(公告)号：US11939380B2

公开(公告)日：2024-03-26

申请号：US16500918

申请日：2018-04-05

Applicant: SYMPHOGEN A/S

Inventor： Trine Lindsted ,  Michael Monrad Grandal ,  Eva Maria Carlsen Melander ,  Camilla Fröhlich ,  Mikkel Wandahl Pedersen ,  Michael Kragh ,  Johan Lantto ,  Monika Gad ,  Ivan David Horak

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06

CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61K2039/507 ,  A61K45/06 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/92

Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

公开(公告)号：US20240091196A1

公开(公告)日：2024-03-21

申请号：US18303267

申请日：2023-04-19

Applicant: Bold Therapeutics, Inc.

Inventor： Suzanne BAKEWELL ,  Jyothi SETHURAMAN

IPC: A61K31/416 ,  A61K31/555 ,  A61K31/7068 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/416 ,  A61K31/555 ,  A61K31/7068 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505

Abstract: IT-139, sodium trans-[tetrachlorobis(lH-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from 1T-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemo-therapy and immuno-oncology agents to be more effective in treating cancer.

公开(公告)号：US11932675B2

公开(公告)日：2024-03-19

申请号：US17067508

申请日：2020-10-09

Applicant: Genentech, Inc. ,  Xencor, Inc.

Inventor： John Desjarlais ,  Matthew Bernett ,  Michael Hedvat ,  Rajat Varma ,  Suzanne Schubbert ,  Christine Bonzon ,  Rumana Rashid ,  Juan Diaz ,  Patrick Holder ,  Christine Huang

IPC: C07K14/00 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  A61K38/00

CPC classification number: C07K14/5443 ,  A61P35/00 ,  C07K16/2818 ,  A61K38/00 ,  C07K2319/30

Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

公开(公告)号：US20240084013A1

公开(公告)日：2024-03-14

申请号：US18517345

申请日：2023-11-22

Applicant: Suzhou Suncadia Biopharmaceuticals Co., Ltd. ,  Jiangsu Hengrui Medicine Co., Ltd. ,  Shanghai Hengrui Pharmaceutical Co., Ltd

Inventor： Xing Sun ,  Guoqing Cao ,  Changyong Yang ,  Lianshan Zhang ,  Yong Guo

IPC: C07K16/28 ,  A61K9/00 ,  A61K31/444 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61K9/0053 ,  A61K31/444 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.

公开(公告)号：US20240081301A1

公开(公告)日：2024-03-14

申请号：US18273631

申请日：2022-01-29

Applicant: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Inventor： Chengzhang Shang ,  Chong Li ,  Chang Liu ,  Dirui Li

IPC: A01K67/027 ,  A61K49/00 ,  C07K14/74 ,  C07K16/28 ,  C12N15/85

CPC classification number: A01K67/0278 ,  A61K49/0008 ,  C07K14/70539 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0325 ,  C07K2317/21 ,  C07K2317/24

Abstract: Provided are genetically modified animal expressing human or chimeric (e.g., humanized) FcRn, and methods of use thereof.

公开(公告)号：US11926668B2

公开(公告)日：2024-03-12

申请号：US17652709

申请日：2022-02-28

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Petra Rietschel ,  Israel Lowy

IPC: C07K16/28 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61K33/243 ,  A61P35/00 ,  A61K45/06

Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.